• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Ashland Board appoints Sanat Chattopadhyay, executive vice president, Merck & Company, as new director effective November 13, 2023

    11/14/23 5:25:00 PM ET
    $ASH
    $MRK
    Specialty Chemicals
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASH alert in real time by email

    WILMINGTON, Del., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has announced the appointment of Sanat Chattopadhyay, executive vice president of Merck & Company (NYSE:MRK) to its Board of Directors. Chattopadhyay will serve on the Board's Environmental, Health, Safety, and Quality and Governance and Nominating Committees, effective November 13, 2023.  Prior to Merck, Chattopadhyay held leadership positions at Wyeth Pharmaceuticals, Aventis, Hoechst Marion Roussel and Hoechst India.

    As previously announced, Jay V. Ihlenfeld who has served as a director since 2017, and Brendan M. Cummins, who joined the board in 2012 have decided not to stand for re-election at Ashland's Annual Stockholders Meeting in January 2024. With the addition of Chattopadhyay, Ashland temporarily increases the size of the Board to 11 members until the next Annual Stockholders Meeting in January 2024.

    Chattopadhyay is a broadly experienced global executive who brings strong industry leadership in manufacturing, distribution, supply chain, and more. He has led complex operations that span 22 countries including cutting-edge manufacturing technology while successfully navigating the ever-changing, globally complex, and heavily regulated industry of biopharmaceuticals.

    "I am pleased to welcome Sanat as a new director to the Ashland Board," said Guillermo Novo, chair and chief executive officer, Ashland. "As we continue to execute our strategy and increase our focus and scale in pharmaceuticals, personal care and coatings, I am confident Sanat will provide important perspectives for our team. And once again, I want to thank Jay and Brendan for their dedicated service to the Board."

    To learn more, visit investor.ashland.com

    About Ashland 

    Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environment, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings, construction, energy, food and beverage, nutraceuticals, personal care and pharmaceutical. Approximately 3,800 passionate, tenacious solvers – from renowned scientists and research chemists to talented engineers and plant operators – thrive on developing practical, innovative and elegant solutions to complex problems for customers in more than 100 countries. Visit ashland.com and ashland.com/ESG to learn more. 

    ™ Trademark, Ashland or its subsidiaries, registered in various countries.

    FOR FURTHER INFORMATION:

    Investor Relations:Media Relations:
    Seth A. MrozekCarolmarie C. Brown
    +1 (302) 594-5010+1 (302) 995-3158
    [email protected][email protected]

    Attachment

    • Ashland_announces_new_board_member_20231114


    Primary Logo

    Get the next $ASH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASH
    $MRK

    CompanyDatePrice TargetRatingAnalyst
    Merck & Company Inc.
    $MRK
    10/13/2025$95.00Neutral
    Citigroup
    Merck & Company Inc.
    $MRK
    9/17/2025$90.00Buy → Hold
    Berenberg
    Ashland Inc.
    $ASH
    9/8/2025$60.00Equal-Weight
    Morgan Stanley
    Merck & Company Inc.
    $MRK
    5/14/2025$84.00Buy → Neutral
    Citigroup
    Ashland Inc.
    $ASH
    5/1/2025Overweight → Equal Weight
    Wells Fargo
    Merck & Company Inc.
    $MRK
    4/22/2025$85.00Neutral
    Cantor Fitzgerald
    Ashland Inc.
    $ASH
    3/26/2025$68.00 → $71.00Neutral → Overweight
    Analyst
    Ashland Inc.
    $ASH
    3/5/2025Buy → Neutral
    Seaport Research Partners
    More analyst ratings

    $ASH
    $MRK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thulin Inge G bought $250,000 worth of shares (2,833 units at $88.25), increasing direct ownership by 2,833% to 2,933 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:09:51 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baker Douglas M Jr bought $1,327,500 worth of shares (15,000 units at $88.50), increasing direct ownership by 1,500% to 16,000 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    2/7/25 4:04:52 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair of the Board and CEO Novo Guillermo bought $2,010,327 worth of shares (31,294 units at $64.24) (SEC Form 4)

    4 - ASHLAND INC. (0001674862) (Issuer)

    2/3/25 4:30:05 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    SEC Filings

    View All

    SEC Form 10-Q filed by Merck & Company Inc.

    10-Q - Merck & Co., Inc. (0000310158) (Filer)

    11/5/25 4:08:41 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASHLAND INC. (0001674862) (Filer)

    11/4/25 5:07:51 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 144 filed by Merck & Company Inc.

    144 - Merck & Co., Inc. (0000310158) (Subject)

    11/3/25 4:09:37 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Financials

    Live finance-specific insights

    View All

    Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026

      Sales of $478 million, down eight percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter. Excluding these initiatives, sales declined one percentIncome from continuing operations of $33 million, or $0.73 per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $50 million, or $1.08 per diluted shareNet income of $32 million, or $0.71 per diluted shareAdjusted EBITDA of $119 million, down four p

    11/4/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Ashland changes start time for fourth-quarter fiscal 2025 earnings conference call webcast

    WILMINGTON, Del., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) has changed the start time of its fourth-quarter fiscal 2025 earnings webcast being held on Wednesday, November 5, 2025. The event will now begin at 10:00 a.m. ET instead of 9:00 a.m. ET.  Attendees that have previously registered do not need to register again. The company's live webcast with securities analysts will include an executive summary and detailed remarks. Simultaneously, the company will post a slide presentation in the Investor Relations section of its website at http://investor.ashland.com. To access the call by phone, please go to this registration link and you will be provided with dial in detail

    10/30/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Merck & Co., Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results

    Total Worldwide Sales Were $17.3 Billion, an Increase of 4% From Third Quarter 2024; Excluding the Impact of Foreign Exchange, Sales Grew 3% KEYTRUDA Sales Grew 10% to $8.1 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 8% WINREVAIR Sales Were $360 Million; Growth of 141% Both Nominally and Excluding the Impact of Foreign Exchange CAPVAXIVE Sales Were $244 Million GARDASIL/GARDASIL 9 Sales Declined 24% to $1.7 Billion; Excluding the Impact of Foreign Exchange, Sales Declined 25% Animal Health Sales Grew 9% to $1.6 Billion; Excluding the Impact of Foreign Exchange, Sales Grew 7% GAAP EPS Was $2.32; Non-GAAP EPS Was $2.58; GAAP and Non-GAAP EPS Include a Ch

    10/30/25 6:30:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASH
    $MRK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup resumed coverage on Merck with a new price target

    Citigroup resumed coverage of Merck with a rating of Neutral and set a new price target of $95.00

    10/13/25 8:54:29 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Merck downgraded by Berenberg with a new price target

    Berenberg downgraded Merck from Buy to Hold and set a new price target of $90.00

    9/17/25 7:56:07 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on Ashland with a new price target

    Morgan Stanley initiated coverage of Ashland with a rating of Equal-Weight and set a new price target of $60.00

    9/8/25 8:48:38 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP,Chief Info&Digital Officer Williams David Michael sold $720,040 worth of shares (8,614 units at $83.59), decreasing direct ownership by 26% to 24,578 units (SEC Form 4)

    4 - Merck & Co., Inc. (0000310158) (Issuer)

    11/4/25 4:02:03 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Bishop Steven D

    4 - ASHLAND INC. (0001674862) (Issuer)

    10/2/25 4:30:10 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form 4 filed by Director Chattopadhyay Sanat

    4 - ASHLAND INC. (0001674862) (Issuer)

    10/2/25 4:30:08 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck's Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef Lipids Trial

    Enlicitide, designed to deliver antibody-like efficacy, has the potential to be the first approved oral PCSK9 inhibitor to lower LDL-C with a safety profile comparable to placebo Enlicitide may help address unmet needs in ASCVD, a key driver of the ongoing cardiovascular (CV) epidemic Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 CORALreef Lipids trial demonstrating that treatment with enlicitide decanoate, an investigational, once-daily oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, resulted in a statistically significant and clinically meaningful reduction in low

    11/8/25 2:30:00 PM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Quebec Expands Public Funding for CAPVAXIVE®

    KIRKLAND, QC, Nov. 5, 2025 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that the province of Quebec has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to their publicly funded adult immunization program. This addition makes the vaccine available to eligible residents in accordance with the province's eligibility criteria, helping to increase access to pneumococcal immunization.    CAPVAXIVE® is approved by Health Canada for use in adults 18 years of age and older for active immunization for the prevention of in

    11/5/25 8:00:00 AM ET
    $MRK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ashland reports fourth quarter fiscal 2025 results and issues outlook for full-year 2026

      Sales of $478 million, down eight percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC), Nutraceuticals and Avoca portfolio optimization initiatives (collectively, Portfolio Optimization) reduced overall sales by approximately $38 million or seven percent versus the prior-year quarter. Excluding these initiatives, sales declined one percentIncome from continuing operations of $33 million, or $0.73 per diluted shareAdjusted Income from Continuing Operations Excluding Intangibles Amortization Expense of $50 million, or $1.08 per diluted shareNet income of $32 million, or $0.71 per diluted shareAdjusted EBITDA of $119 million, down four p

    11/4/25 5:01:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Ashland Inc.

    SC 13G - ASHLAND INC. (0001674862) (Subject)

    11/12/24 11:54:03 AM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Ashland Inc.

    SC 13G/A - ASHLAND INC. (0001674862) (Subject)

    7/10/24 1:14:41 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    SEC Form SC 13D/A filed by Ashland Inc. (Amendment)

    SC 13D/A - ASHLAND INC. (0001674862) (Subject)

    4/25/24 4:15:12 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    $ASH
    $MRK
    Leadership Updates

    Live Leadership Updates

    View All

    REPAY Appoints New Chief Financial Officer

    Repay Holdings Corporation (NASDAQ:RPAY) ("REPAY" or the "Company"), a leading provider of integrated payment processing solutions, today announced the appointment of Robert Houser as Chief Financial Officer of the Company, effective September 8, 2025. "We are extremely excited to welcome Rob to REPAY. Rob brings over a decade of divisional CFO and operational experience within the payment industry to help him contribute immediately. Rob has held key strategic roles across his career and will be a great partner in running our company," said John Morris, Co-Founder and CEO. Most recently, Rob served as the Group CFO of the Public Sector and Advisor at Conduent Incorporated (NASDAQ:CNDT)

    8/11/25 4:06:00 PM ET
    $CNDT
    $FI
    $IART
    Real Estate
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Ashland announces executive leadership changes

    WILMINGTON, Del., May 05, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that Kevin Willis, senior vice president and chief financial officer, has decided to leave Ashland to pursue another opportunity. His last day with the company will be May 16, 2025. Willis joined Ashland in 1987 as an associate auditor in the internal audit department. He has served in various management positions of increasing responsibility, including leading teams on major projects in the business services, information technology, accounting and finance areas. Willis' departure is not the result of any disagreement with the company related to its financial statements, internal control over finan

    5/5/25 5:00:00 PM ET
    $ASH
    Specialty Chemicals
    Consumer Discretionary

    GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    2/18/25 9:00:00 AM ET
    $AMGN
    $GSK
    $JNJ
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components